Ohio State Professor Receives Patent For Infectious Bursal Disease Virus Detection Kit

October 29, 1998

COLUMBUS, Ohio -- An Ohio State University researcher has been awarded a patent for a test that can detect the presence of antibodies for a chicken virus that can be economically devastating.

The test is an ELISA assay and detects antibodies to infectious bursal disease virus (IBDV), a disease that can make chickens susceptible to future illness and infection. The same researcher has a patent pending for an IBD-PCR test, which determines if chickens in a flock currently have the virus. Both tests are now commercially available.

Use of these tests can tell farmers if their chickens need to be vaccinated against IBDV, and if so, which vaccine to choose.

Chicken farming is a multi-billion dollar industry in the United States. IBDV is the second-leading cause of viral disease in chickens. The first is infectious bronchitis virus, a respiratory disease.

“Neither disease is deadly, but each is important from an economic standpoint,” said Daral Jackwood, principal developer of the two tests and professor of molecular virology at the Ohio Agricultural Research and Development Center.

“A producer won’t get the same performance out of his flock. It’s going to cost more to feed the birds and the birds will weigh less when they go to market. It can be economically devastating, resulting in the loss of tens of millions of dollars.”

The ELISA assay requires drawing blood samples from chickens. This test determines how well the chickens are protected from strains of the virus -- in other words, how much antibody they have in their system. Higher antibody levels mean greater protection. Jackwood said older ELISA tests weren’t able to detect antibodies to specific strains of IBDV.

“Our test correlates much better with protection,” he said. “The antibody concentrations we get reflect how well-protected those birds are.”

The IBD-PCR test is used to test for the presence of IBDV in a chicken flock. About six chickens are killed and cells are extracted from the bursa – a sac located inside the bird at the base of the tail. The virus can be found in cells of bursa tissue. The first of its kind, this test tells farmers which strain, or strains, of IBDV their flock has been exposed to.

“The farmer will then know what strain is causing problems on his farm so when the next group of chickens comes in, he can select the proper vaccine,” Jackwood said. Worldwide, there are currently about two dozen vaccines for IBDV and at least an equal number of viral strains.

IBDV, first discovered in this country in the late 1950s, affects the immune system of young chickens. Signs of the disease include loss of appetite and low weight gain.

The disease favors chickens younger than 7 weeks old because these animals have immature immune cells. The virus replicates in and destroys the immature cells.

“If two or three percent of chickens on a farm have the disease, 100 percent of the flock will have it within a couple of days,” Jackwood said.

IBDV received additional attention in 1997, when researchers discovered the virus had infected certain populations of Antarctic penguins. Jackwood is currently testing the tissues of penguins using the IBD-PCR test to determine which strains of virus are present in these animals.

Jackwood received the ELISA assay patent in July.Renee Jackwood, formerly a research associate in veterinary medicine, helped develop the tests. IDEXX Laboratories, Inc., based in Westbrook, Maine, manufactures the ELISA assay and IBD-PCR test.


Ohio State University

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.